Observes prostate cancer patients who have a few spread tumours
Follows people newly diagnosed with prostate cancer that has spread to a few sites.
Plain-language title generated from the registry record
Registry title: OLIGOS: Impact of Treatment on Primary Tumour in Patients With Newly Diagnosed Oligometastatic Neoplasia of the Prostate
Key facts
- Where
- Abano Terme, Bassano del Grappa, Brixen, Dolo, Mestre, Padova, Trieste, Udine, and Verona, ItalySee the 12 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men newly diagnosed with prostate cancer that has spread to only a few places. They must not have had treatment of the prostate tumour yet.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Newly diagnosed prostate cancer confirmed by biopsy, with low-volume spread: fewer than 4 bone metastases and no visceral metastases. Any risk category. No neuroendocrine differentiation.
- Earlier treatment
- No earlier treatment of the prostate tumour (such as prostate removal surgery or radiotherapy). Hormone or other systemic therapy for less than 6 months before joining is allowed.
Main reasons for not taking part
- High-volume spread (4 or more bone metastases, or visceral metastases)
- ECOG performance status above 1
- Already taking part in another clinical trial
- Reasons that prevent hormone or systemic therapy
- Earlier treatment of the primary tumour
Read by machine on 12 November 2026.
Where in Italy
- Casa di Cura Abano TermeAbano Terme, ItalyContact: Daniele Romagnoli, MDTaking people
- Ospedale di Bassano Del GrappaBassano del Grappa, ItalyContact: Antonio Celia, MDTaking people
- Ospedale di BressanoneBrixen, ItalyContact: Michael Aigner, MDNot yet recruiting
- Ospedale di DoloDolo, ItalyContact: Gianna Pace, MDTaking people
- Ospedale dell'Angelo - MestreMestre, ItalyContact: Francesco Gerardo Mandato, MDTaking people
- Azienda Ospedale Universita PadovaPadova, ItalyContact: Fabio Zattoni, MDNot yet recruiting
- Istituto Oncologico Veneto - IRCCSPadova, ItalyContact: Angelo Porreca, MDTaking people
- Ospedale MAter Salutis - LegnagoPadova, ItalyContact: Pierpaolo Curti, MDNot yet recruiting
- Ospedali Riuniti Padova SudPadova, ItalyContact: Nicola Zanovello, MDTaking people
- Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI)Trieste, ItalyContact: Carlo Trombetta, MDNot yet recruiting
- Presidio Ospedaliero Universitario Santa Maria della Misericorida (ASU FC)Udine, ItalyContact: Gianluca Giannarini, MDNot yet recruiting
- Azienda Ospedaliera Universitaria Integrata VeronaVerona, ItalyContact: Alessandro Antonelli, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Istituto Oncologico Veneto IRCCS
- Trial code
- NCT06273345
- Record updated
- 17 April 2025
- Original description
The proposed study consists of a multicentre prospective observational study involving patients with oligometastatic prostatic neoplasia defined according to CHAARTED criteria.Read full original descriptionShow less
OLIGOS: Impact of Treatment on Primary Tumour in Patients With Newly Diagnosed Oligometastatic Neoplasia of the Prostate
The proposed study consists of a multicentre prospective observational study involving patients with oligometastatic prostatic neoplasia defined according to CHAARTED criteria.
The aim of the study is the creation of a registry including patients with newly diagnosed OMPCa, belonging to the main urological centres in the Triveneto region, in order to evaluate the oncological outcomes and the impact on the quality of life of local treatment of the primary neoplasm (surgical or radiotherapy) in addition to systemic hormonal treatment (ADT as monotherapy or in combination with Docetaxel/androgen receptor signal inhibitors (ARTA)).
The above criteria define 'high metastatic volume' disease with the following parameters
* ≥ 4 bone metastases, including at least one outside the spine and pelvis * Presence of visceral metastases Consequently, patients included in the study should not have the above-mentioned characteristics.
Inclusion: Diagnosis of new-onset prostate neoplasia (any risk category according to EAU guidelines); Histological confirmation of disease by prostate biopsies. Absence of neuroendocrine differentiation; Low volume of metastatic disease defined according to CHAARTED study criteria (< of 4 bone metastases, absence of visceral metastases); Patients without previous treatment of primary malignancy (e.g. previous radical prostatectomy, previous RT); Patients treated with systemic therapy (ADT as monotherapy or in combination) for less than 6 months prior to enrolment; Eastern Cooperative Oncology Group (ECOG) performance status 0-1; Patients eligible for local treatment of primary malignancy and concomitant systemic therapy; Signature of informed consent.
Exclusion: Contraindications to hormone/systemic therapy administration; Previous treatment of primary tumour (RP, RT or other treatment of primary tumour); High volume metastatic disease defined according to CHARTEED criteria; Inability or unwillingness to give written informed consent; ECOG performance status > 1; Patients included in other clinical trials.